Clinical trial
Efficacy and Safety of Opicapone in Clinical Practice
NCT02847442 · Bial - Portela C S.A., Industry · Completed
Key facts
| NCT number | NCT02847442 |
|---|---|
| Title | Efficacy and Safety of Opicapone in Clinical Practice |
| Official title | Efficacy and Safety of Opicapone in Clinical Practice in Parkinson's Disease Patients With Wearing-off Motor Fluctuations |
| Acronym | OPTIPARK |
| Lead sponsor | Bial - Portela C S.A., Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Parkinson's Disease With Wearing-off Motor Fluctuations |
| Intervention type | Drug |
| Interventions | BIA 9-1067, levodopa/dopa decarboxylase inhibitor |
| Enrollment | 518 |
| Start date | Nov 23, 2016 |
| Primary completion | Jul 4, 2018 |
| Completion | Jul 4, 2018 |
| First posted | Jul 28, 2016 |
| Last update posted | Oct 15, 2018 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: